• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物物理状态对热熔挤出法制备的固体分散体溶出度增强的影响:以奥氮平为例的研究

The influence of drug physical state on the dissolution enhancement of solid dispersions prepared via hot-melt extrusion: a case study using olanzapine.

作者信息

Pina Maria Fátima, Zhao Min, Pinto João F, Sousa João J, Craig Duncan Q M

出版信息

J Pharm Sci. 2014 Apr;103(4):1214-23. doi: 10.1002/jps.23894.

DOI:10.1002/jps.23894
PMID:24765654
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4241582/
Abstract

In this study, we examine the relationship between the physical structure and dissolution behavior of olanzapine (OLZ) prepared via hot-melt extrusion in three polymers [polyvinylpyrrolidone (PVP) K30, polyvinylpyrrolidone-co-vinyl acetate (PVPVA) 6:4, and Soluplus® (SLP)]. In particular, we examine whether full amorphicity is necessary to achieve a favorable dissolution profile. Drug–polymer miscibility was estimated using melting point depression and Hansen solubility parameters. Solid dispersions were characterized using differential scanning calorimetry, X-ray powder diffraction, and scanning electron microscopy. All the polymers were found to be miscible with OLZ in a decreasing order of PVP>PVPVA>SLP. At a lower extrusion temperature (160°C), PVP generated fully amorphous dispersions with OLZ, whereas the formulations with PVPVA and SLP contained 14%-16% crystalline OLZ. Increasing the extrusion temperature to 180°C allowed the preparation of fully amorphous systems with PVPVA and SLP. Despite these differences, the dissolution rates of these preparations were comparable, with PVP showing a lower release rate despite being fully amorphous. These findings suggested that, at least in the particular case of OLZ, the absence of crystalline material may not be critical to the dissolution performance. We suggest alternative key factors determining dissolution, particularly the dissolution behavior of the polymers themselves.

摘要

在本研究中,我们考察了通过热熔挤出法制备的奥氮平(OLZ)在三种聚合物[聚乙烯吡咯烷酮(PVP)K30、聚乙烯吡咯烷酮-醋酸乙烯酯共聚物(PVPVA)6:4和固体分散体聚合物(Soluplus®,SLP)]中的物理结构与溶出行为之间的关系。特别是,我们考察了是否需要完全非晶态才能获得良好的溶出曲线。使用熔点降低和汉森溶解度参数来评估药物-聚合物的混溶性。通过差示扫描量热法、X射线粉末衍射和扫描电子显微镜对固体分散体进行表征。结果发现,所有聚合物与OLZ均具有混溶性,其混溶性顺序为PVP>PVPVA>SLP。在较低的挤出温度(160°C)下,PVP与OLZ形成了完全非晶态的分散体,而含有PVPVA和SLP的制剂中含有14%-16%的结晶性OLZ。将挤出温度提高到180°C可制备出含有PVPVA和SLP的完全非晶态体系。尽管存在这些差异,但这些制剂的溶出速率相当,PVP尽管是完全非晶态,但其释放速率较低。这些发现表明,至少在OLZ的特定情况下,无定形材料的不存在对溶出性能可能并不关键。我们提出了决定溶出的其他关键因素,特别是聚合物本身的溶出行为。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/b3f122efcb22/jps0103-1214-f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/5a5086606cd0/jps0103-1214-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/0ae234fd9dac/jps0103-1214-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/a4a76d633c8f/jps0103-1214-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/55b80794b5cc/jps0103-1214-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/0b5b295ac6ba/jps0103-1214-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/d4e997e0846b/jps0103-1214-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/e16ab840eafe/jps0103-1214-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/3e7c247bf58e/jps0103-1214-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/67526f65ceca/jps0103-1214-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/b3f122efcb22/jps0103-1214-f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/5a5086606cd0/jps0103-1214-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/0ae234fd9dac/jps0103-1214-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/a4a76d633c8f/jps0103-1214-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/55b80794b5cc/jps0103-1214-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/0b5b295ac6ba/jps0103-1214-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/d4e997e0846b/jps0103-1214-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/e16ab840eafe/jps0103-1214-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/3e7c247bf58e/jps0103-1214-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/67526f65ceca/jps0103-1214-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934f/4241582/b3f122efcb22/jps0103-1214-f10.jpg

相似文献

1
The influence of drug physical state on the dissolution enhancement of solid dispersions prepared via hot-melt extrusion: a case study using olanzapine.药物物理状态对热熔挤出法制备的固体分散体溶出度增强的影响:以奥氮平为例的研究
J Pharm Sci. 2014 Apr;103(4):1214-23. doi: 10.1002/jps.23894.
2
Five-Stage Approach for a Systematic Screening and Development of Etravirine Amorphous Solid Dispersions by Hot-Melt Extrusion.五阶段方法通过热熔挤出法对依曲韦林无定形固体分散体进行系统筛选和开发。
Mol Pharm. 2020 Feb 3;17(2):554-568. doi: 10.1021/acs.molpharmaceut.9b00996. Epub 2020 Jan 23.
3
Development of Tablet Formulation of Amorphous Solid Dispersions Prepared by Hot Melt Extrusion Using Quality by Design Approach.采用质量源于设计方法通过热熔挤出制备无定形固体分散体片剂配方的研究
AAPS PharmSciTech. 2016 Feb;17(1):214-32. doi: 10.1208/s12249-015-0472-0. Epub 2016 Jan 12.
4
Continuous production of itraconazole-based solid dispersions by hot melt extrusion: Preformulation, optimization and design space determination.通过热熔挤出法连续生产基于伊曲康唑的固体分散体:处方前研究、优化及设计空间确定
Int J Pharm. 2016 Dec 30;515(1-2):114-124. doi: 10.1016/j.ijpharm.2016.10.003. Epub 2016 Oct 5.
5
Characterization and stability of solid dispersions based on PEG/polymer blends.基于 PEG/聚合物共混物的固体分散体的特性和稳定性。
Int J Pharm. 2010 May 10;390(2):165-73. doi: 10.1016/j.ijpharm.2010.01.039. Epub 2010 Feb 10.
6
A comparative study between hot-melt extrusion and spray-drying for the manufacture of anti-hypertension compatible monolithic fixed-dose combination products.热熔挤出法与喷雾干燥法在抗高血压单片固定剂量复方制剂中的比较研究。
Int J Pharm. 2018 Jul 10;545(1-2):183-196. doi: 10.1016/j.ijpharm.2018.05.008. Epub 2018 May 3.
7
An investigation into the influence of drug-polymer interactions on the miscibility, processability and structure of polyvinylpyrrolidone-based hot melt extrusion formulations.药物-聚合物相互作用对聚乙烯吡咯烷酮基热熔挤出制剂的混溶性、加工性能和结构的影响研究。
Int J Pharm. 2015 Dec 30;496(1):95-106. doi: 10.1016/j.ijpharm.2015.09.063. Epub 2015 Sep 30.
8
Solid microcrystalline dispersion films as a new strategy to improve the dissolution rate of poorly water soluble drugs: A case study using olanzapine.固体微结晶分散体薄膜作为一种提高难溶性药物溶解速率的新策略:以奥氮平为例。
Int J Pharm. 2016 Jul 11;508(1-2):42-50. doi: 10.1016/j.ijpharm.2016.05.012. Epub 2016 May 3.
9
Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution.利托那韦无定形固体分散体在水合和溶解过程中的相行为。
Pharm Res. 2017 Dec;34(12):2842-2861. doi: 10.1007/s11095-017-2265-5. Epub 2017 Sep 27.
10
An Insight Into the Impact of Polymers on the Hydrate Conversion of Olanzapine Form I in Aqueous Suspensions.聚合物对奥氮平晶型I在水悬浮液中水合物转化影响的洞察
J Pharm Sci. 2017 Jul;106(7):1786-1794. doi: 10.1016/j.xphs.2017.03.007. Epub 2017 Mar 16.

引用本文的文献

1
3D-Printed Tablets of Nifurtimox: In Vitro and In Vivo Anti- Studies.硝呋替莫的3D打印片剂:体外和体内抗研究
Pharmaceutics. 2025 Jan 9;17(1):80. doi: 10.3390/pharmaceutics17010080.
2
Sweeteners Show a Plasticizing Effect on PVP K30-A Solution for the Hot-Melt Extrusion of Fixed-Dose Amorphous Curcumin-Hesperetin Solid Dispersions.甜味剂对用于热熔挤出固定剂量无定形姜黄素-橙皮素固体分散体的PVP K30溶液具有增塑作用。
Pharmaceutics. 2024 May 15;16(5):659. doi: 10.3390/pharmaceutics16050659.
3
Preparation of Hot-Melt-Extruded Solid Dispersion Based on Pre-Formulation Strategies and Its Enhanced Therapeutic Efficacy.

本文引用的文献

1
Polymorphic form IV of olanzapine.奥氮平多晶型IV
Acta Crystallogr C. 2011 Nov;67(Pt 11):o461-3. doi: 10.1107/S0108270111043952. Epub 2011 Oct 31.
2
Evaluation of amorphous solid dispersion properties using thermal analysis techniques.利用热分析技术评价无定形固体分散体的性质。
Adv Drug Deliv Rev. 2012 Apr;64(5):396-421. doi: 10.1016/j.addr.2011.07.009. Epub 2011 Aug 4.
3
Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations.
基于处方前策略的热熔挤出固体分散体的制备及其增强的治疗效果。
Pharmaceutics. 2023 Nov 30;15(12):2704. doi: 10.3390/pharmaceutics15122704.
4
Voriconazole Cyclodextrin Based Polymeric Nanobeads for Enhanced Solubility and Activity: In Vitro/In Vivo and Molecular Simulation Approach.基于环糊精的伏立康唑聚合物纳米珠用于提高溶解度和活性:体外/体内及分子模拟方法
Pharmaceutics. 2023 Jan 24;15(2):389. doi: 10.3390/pharmaceutics15020389.
5
Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends.非晶态和共非晶态奥氮平粉末混合物的下游处理
Pharmaceutics. 2022 Jul 23;14(8):1535. doi: 10.3390/pharmaceutics14081535.
6
Modulating Drug Release from Short Poly(ethylene glycol) Block Initiated Poly(L-lactide) Di-block Copolymers.短聚乙二醇引发的聚 L-乳酸两嵌段共聚物调控药物释放。
Pharm Res. 2023 Jul;40(7):1697-1707. doi: 10.1007/s11095-022-03228-8. Epub 2022 Apr 26.
7
Hot-Melt Extrusion: a Roadmap for Product Development.热熔挤出:产品开发路线图。
AAPS PharmSciTech. 2021 Jun 17;22(5):184. doi: 10.1208/s12249-021-02017-7.
8
Influence of Polyvinyl Alcohol (PVA) on PVA-Poly-N-hydroxyethyl-aspartamide (PVA-PHEA) Microcrystalline Solid Dispersion Films.聚乙烯醇(PVA)对 PVA-聚-N-羟乙基天冬酰胺(PVA-PHEA)微晶固体分散体薄膜的影响。
AAPS PharmSciTech. 2020 Oct 2;21(7):267. doi: 10.1208/s12249-020-01811-z.
9
Orodispersible Polymer Films with the Poorly Water-Soluble Drug, Olanzapine: Hot-Melt Pneumatic Extrusion for Single-Process 3D Printing.含难溶性药物奥氮平的口腔崩解聚合物薄膜:用于单步3D打印的热熔气动挤出法
Pharmaceutics. 2020 Jul 22;12(8):692. doi: 10.3390/pharmaceutics12080692.
10
Spray-Drying, Solvent-Casting and Freeze-Drying Techniques: a Comparative Study on their Suitability for the Enhancement of Drug Dissolution Rates.喷雾干燥、溶剂浇铸和冷冻干燥技术:提高药物溶出率的适用性比较研究。
Pharm Res. 2020 Feb 19;37(3):57. doi: 10.1007/s11095-020-2778-1.
固体分散体改善亲脂性药物的溶出行为:从生产工艺角度出发考虑制剂问题。
Expert Opin Drug Deliv. 2011 Sep;8(9):1121-40. doi: 10.1517/17425247.2011.598147. Epub 2011 Jul 2.
4
Prediction of the thermal phase diagram of amorphous solid dispersions by Flory-Huggins theory.利用 Flory-Huggins 理论预测非晶态固体分散体的热相图。
J Pharm Sci. 2011 Aug;100(8):3196-3207. doi: 10.1002/jps.22541. Epub 2011 Mar 17.
5
Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.药物-聚合物的溶解度和混溶性:无定形固体分散体开发中的稳定性考虑和实际挑战。
J Pharm Sci. 2010 Jul;99(7):2941-7. doi: 10.1002/jps.22074.
6
Review: physical chemistry of solid dispersions.综述:固体分散体的物理化学。
J Pharm Pharmacol. 2009 Dec;61(12):1571-86. doi: 10.1211/jpp/61.12.0001.
7
Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug.熔融挤出技术在难溶性药物物理化学稳定的高能无定形固体分散体开发中的应用。
Mol Pharm. 2008 Nov-Dec;5(6):994-1002. doi: 10.1021/mp8001073.
8
Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters.利用实验测定的相互作用参数估算药物与聚合物在无定形固体分散体中的混溶性和溶解度。
Pharm Res. 2009 Jan;26(1):139-51. doi: 10.1007/s11095-008-9721-1. Epub 2008 Sep 9.
9
Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.固体分散体作为提高难溶性药物口服生物利用度的策略。
Drug Discov Today. 2007 Dec;12(23-24):1068-75. doi: 10.1016/j.drudis.2007.09.005. Epub 2007 Oct 30.
10
Pharmaceutical applications of hot-melt extrusion: Part II.热熔挤出技术的药物应用:第二部分。
Drug Dev Ind Pharm. 2007 Oct;33(10):1043-57. doi: 10.1080/03639040701525627.